CW
CVKD icon

Curio Wealth’s Cadrenal Therapeutics CVKD Stock Holding History

Curio Wealth’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5 Hold
1
– – ﹤0.01% 1245
2025
Q4 		$7 Buy
+1
New +$11 ﹤0.01% 460

Other funds holding CVKD

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $914M AUM 18.14% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Curio Wealth's CVKD Position: Q1 2026 in Review

Curio Wealth held its Cadrenal Therapeutics (CVKD) position steady in Q1 2026 at 1 share worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Curio Wealth first reported a position in CVKD in Q4 2025 and has held it in 2 quarters since. The position peaked at $7 in Q4 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • Curio Wealth held 1 share of Cadrenal Therapeutics worth $5 as of Q1 2026.
  • Curio Wealth left its Cadrenal Therapeutics share count unchanged in Q1 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Curio Wealth's portfolio in Q1 2026, its #1245 holding.
  • Curio Wealth first reported a position in Cadrenal Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Curio Wealth's Cadrenal Therapeutics position peaked at $7 in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on Curio Wealth's 13F filing for Q1 2026, filed 12 May 2026.